Immuno-Oncology

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

Stephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

Immune checkpoint blockade has transformed the treatment paradigms of multiple advanced solid tumors-and bladder cancer is no exception.

Toni Choueiri, MD, Dana-Farber Cancer, Clinical Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Dana Farber Cancer, discusses the potential for combination treatments in kidney cancer.

Marianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses immune-mediated adverse events in lung cancer.

The FDA has granted a breakthrough therapy designation to pembrolizumab as a potential therapy for patients with microsatellite instability-high metastatic colorectal cancer.

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.

Heather Wakelee, MD, reflected on the evolution of lung cancer treatment and just how significant of an impact immunotherapies may have.

PD-1/PD-L1 agents have shown significant potential for the treatment of urothelial bladder cancer, Daniel Petrylak, MD, from Yale Cancer Center, noted in a recent interview with OncLive.

The prospect of combining PD-1 inhibitors with existing therapies, particularly brentuximab vedotin, is emerging as the most exciting new development in advancing the treatment of patients with Hodgkin lymphoma, raising the possibility of improving the cure rates in a disease where standard strategies have already produced notable results.

The FDA expanded the approval of ipilimumab (Yervoy) in melanoma to include adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

The FDA has approved talimogene laherparepvec for the treatment of patients with advanced melanoma.

Pembrolizumab (Keytruda) extended overall survival versus docetaxel in the phase II/III KEYNOTE-010 trial.

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.

Abnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.

Talimogene laherparepvec has received a positive recommendation from the CHMP, which suggests that the treatment should gain European approval for patients with advanced melanoma.

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

Raffit Hassan, MD, Co-Chief Thoracic and Gastrointestinal Oncology Branch, Senior Investigator Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute, discusses a recent phase IB trial investigating avelumab in unresectable mesothelioma.